Scientific deep-dive
Buy Tirzepatide as a Research Peptide? Why It Is Illegal and Unsafe
Tirzepatide sold as a 'research peptide' is unlawful for personal use and unverified for identity, purity, sterility, or dose. FDA enforcement-discretion for compounded tirzepatide ended Feb 2025 (503A) / Mar 2025 (503B). Legal paths: Mounjaro or Zepbound by prescription.
This evidence review is part of Weight Loss Rankings’ living editorial database — 1,160+ research articles and 630+ editorially reviewed GLP-1 telehealth providers, sourced only from FDA prescribing information on DailyMed and peer-reviewed PubMed literature.
Search “buy tirzepatide peptide” and the first page of results is a mix of chemistry-supply websites selling lyophilized tirzepatide vials for $80 to $300, all labeled “for research use only, not for human consumption.” This article is a hard debunker. The research-use disclaimer is the seller’s legal shield, not a quality guarantee, and it does not legalize personal therapeutic use. The FDA enforcement-discretion grace period that allowed broad compounded tirzepatide ended February 18, 2025 (503A state-licensed pharmacies) and March 19, 2025 (503B outsourcing facilities). As of November 2026, the only legal paths to tirzepatide are FDA-approved Mounjaro or Zepbound by prescription.
The honest answer
It is illegal in the United States to purchase tirzepatide as a “research peptide” for personal therapeutic use. Such products are sold under “research use only” disclaimers and have no FDA quality, purity, sterility, or dose verification. The FDA enforcement-discretion grace period for compounded tirzepatide ended February 18, 2025 (503A) and March 19, 2025 (503B). The only legal paths to tirzepatide are Mounjaro or Zepbound by prescription.
What “research-chemical tirzepatide” actually is
Tirzepatide, the active ingredient in Mounjaro and Zepbound, is a 39-amino-acid synthetic peptide that acts as a dual GIP and GLP-1 receptor agonist. Its full chemical structure was first published in 2018 by Coskun and colleagues at Eli Lilly, who gave its molecular weight as 4,810.52 Daltons. [1] The molecule itself is not a trade secret. Its synthesis can be replicated by any laboratory with solid-phase peptide synthesis equipment.
That replicability is what creates the “research peptide” market. Chemistry-supply vendors — some operating from U.S. addresses, more frequently from overseas — synthesize tirzepatide as a lyophilized powder, ship it in glass vials with bacteriostatic-water reconstitution kits, and label the package “for research use only, not for human consumption.” The price is typically $80 to $300 for a 10 mg or 30 mg vial, roughly 60-90% below the cash price of brand Zepbound or Mounjaro.
The marketing pages often imply, without explicitly stating, that the product is for human injection: dosing tables in “research” units that coincidentally match clinical doses, reconstitution diagrams that show subcutaneous injection sites, customer reviews on forums describing weight loss outcomes. The seller’s legal position is that the package says “not for human consumption” and what the customer does next is the customer’s choice.
That legal position is wrong on multiple counts.
Why personal-use research-chemical purchase is illegal
Tirzepatide is a Class C prescription drug under the Federal Food, Drug, and Cosmetic Act (FDCA). The only FDA-approved tirzepatide products are Mounjaro (NDA 215866, approved May 13, 2022 for type 2 diabetes) and Zepbound (NDA 217806, approved November 8, 2023 for chronic weight management). [10] No generic tirzepatide has FDA approval or tentative approval as of November 2026; Eli Lilly’s composition-of-matter patent runs into the 2030s. There is no “generic tirzepatide” product, no 503B-stocked branded equivalent, and no FDA-approved unbranded equivalent.
Any tirzepatide that does not come from a prescription against the approved NDAs is, by definition, an unapproved new drug under FDCA § 505(a). The seller’s distribution is unlawful under FDCA § 301(d). The buyer’s self-administration is the use of an unapproved new drug. The lab-supply disclaimer “not for human consumption” is the seller’s defense against the charge of distributing for human use; it does not retroactively make personal-use injection legal for the buyer.
FDA’s standing advisory FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss summarizes the agency’s position: unapproved tirzepatide and semaglutide products marketed for weight loss have no FDA review of identity, purity, strength, or sterility, and consumers who use them do so without the safety net of the federal drug-approval system. [6]
Three things the “research use only” disclaimer is not
- It is not a legal license for the buyer to inject.
- It is not a quality guarantee — no USP identity, purity, or sterility testing is implied.
- It is not equivalent to FDA approval, IND status, or 503A/503B compounding authority.
The compounded-tirzepatide regulatory cliff (February/March 2025)
Many people searching for “buy tirzepatide peptide” today are actually looking for what used to be available in 2023-2024: compounded tirzepatide from a state-licensed pharmacy at $200-$400 per month under the FDA Drug Shortage List enforcement-discretion framework. That window has closed.
The relevant FDA timeline, anchored to the agency’s December 19, 2024 Declaratory Order: [4] [5]
| Date | Event |
|---|---|
| October 2, 2024 | FDA initial determination — tirzepatide shortage resolved; removed from FDA Drug Shortage List. |
| October 11, 2024 | Court order on FDA motion remanded the decision to the agency for reevaluation following compounder litigation. |
| December 19, 2024 | FDA Declaratory Order reconfirmed tirzepatide shortage is resolved; set enforcement-discretion timeline for compounders. |
| February 18, 2025 | 503A state-licensed pharmacy enforcement-discretion ENDED for compounded tirzepatide. |
| March 19, 2025 | 503B outsourcing-facility enforcement-discretion ENDED for compounded tirzepatide. |
| February 21, 2025 | FDA declared injectable semaglutide shortage resolved (parallel timeline; 503A ended April 22, 2025 / 503B ended May 22, 2025). |
As of November 2026, the practical compounded-tirzepatide landscape is:
- Broad commercial compounded tirzepatide — the $200-$400/month telehealth model that dominated 2024 — is no longer permitted under section 503A or 503B enforcement discretion.
- Patient-specific 503A compounded tirzepatide for documented clinical-necessity cases (e.g., proven allergy to a Zepbound or Mounjaro inactive ingredient, documented dose not available in the approved product) remains legal under traditional 503A authority — but this is a narrow medical-necessity carve-out, not a commercial business model.
- “Research peptide” tirzepatide was never on the legal side of the 503A/503B framework. It is and was the sale of an unapproved new drug outside the compounding regulatory structure entirely.
For the deeper breakdown of the compounded-vs-brand-vs-research-peptide regulatory map — including the difference between 503A and 503B authority, what survives post-shortage, and how legitimate compounded suppliers verify themselves — see our companion piece on buying tirzepatide online: how to verify pharmacy legitimacy.
FDA enforcement on gray-market peptide sellers
Federal enforcement against unapproved-tirzepatide sellers operates on five tracks, often simultaneously:
- FDA Warning Letters. Public letters issued by the Office of Unapproved Drugs and Labeling Compliance demanding corrective action. The full searchable archive is on FDA.gov; entries tagged GLP-1, peptide, semaglutide, or tirzepatide have grown substantially since 2023.
- FDA import alerts. Categorical inbound shipment holds at Customs and Border Protection for products identified as unapproved new drugs. Personal-importation small-quantity policy does not cover any drug for which an FDA-approved version exists domestically; tirzepatide is unambiguously in that category.
- Civil and criminal injunctions. Department of Justice civil enforcement under FDCA § 302; criminal prosecution where the conduct is willful and the volume material.
- Asset forfeiture. Coordinated with DOJ Asset Forfeiture and Money Laundering Section; payment processors and banking relationships often unwound.
- FDA Tainted Weight Loss Products database. Public listing of products found to contain undisclosed pharmaceutical ingredients or to be misbranded with unsubstantiated weight-loss claims. [6]
From the buyer’s perspective, the most common outcomes are not federal charges — though those do occur for larger purchases or resale activity — but rather: shipments seized at Customs (no product, no refund), payment-processor reversals after the seller’s account is unwound, sellers who simply stop responding, and the absence of any recourse if the product is contaminated, sub-potent, super-potent, or simply not tirzepatide.
Counterfeit tirzepatide and semaglutide in the legitimate supply chain
The counterfeit risk is not theoretical. In December 2023 the FDA warned consumers about counterfeit Ozempic 1 mg lot NAR0074 (semaglutide) that had infiltrated the legitimate U.S. drug supply chain; the agency seized thousands of units. Subsequent FDA analysis confirmed the needles were counterfeit and sterility could not be verified, posing infection risk. [9] If counterfeit semaglutide can reach FDA-registered wholesalers, the contamination probability for vials shipped from unregistered chemistry suppliers is materially higher.
Purity, sterility, and dose: what you don’t get with research chemicals
FDA-approved Zepbound and Mounjaro carry a multi-layered quality framework: cGMP manufacturing at FDA-inspected facilities, USP-grade identity testing, USP <71> sterility testing, USP <85> bacterial endotoxin testing, batch release certificates, lot-level traceability, and pharmacovigilance reporting under the FDA Adverse Event Reporting System (FAERS). Legitimately compounded tirzepatide, when it was permitted, carried a partial version of that framework through 503A or 503B compounding standards.
Research-chemical tirzepatide carries none of that. The relevant gaps:
| Quality dimension | FDA-approved Zepbound / Mounjaro | 503A patient-specific compounded | “Research peptide” tirzepatide |
|---|---|---|---|
| Identity (is it tirzepatide?) | USP identity testing; FDA-registered API supplier | USP identity; FDA-registered API supplier required | No verified identity testing |
| Purity (impurity profile) | USP <466> impurity limits; ICH Q3 compliant | USP impurity testing required by state pharmacy law | Unverified; foreign-synthesis impurities possible |
| Sterility | USP <71> sterility testing at batch release | USP <797> sterile compounding standards | No sterility testing required or performed |
| Bacterial endotoxin | USP <85> endotoxin testing | Endotoxin testing per state pharmacy law | No endotoxin testing |
| Dose accuracy | Prefilled pen with calibrated injector | Pharmacist-calibrated; labeled for the specific patient | Patient-reconstitutes; high unit-conversion error risk |
| Recourse on adverse event | FAERS; manufacturer liability; FDA recall authority | State board of pharmacy; pharmacist liability | None; seller often offshore and anonymous |
The dose-error risk is well documented. A 2023 case series in the Journal of the American Pharmacists Association (Lambson et al., PMID 37392810) described 3 patients reported to a U.S. regional poison control center after incorrect doses of compounded semaglutide obtained from compounding pharmacies and an aesthetic spa. Two had self-administered 10-fold dosing errors, one reported dosing in milliliters and units rather than milligrams, and the authors note that syringes not intended for semaglutide add to the confusion over dosing units. [3] The FDA followed in October 2024 with an alert covering compounded injectable semaglutide dosing errors. [8] Both findings concern compounded semaglutide, not brand-name pens. Research-chemical tirzepatide adds the additional layer of unverified identity and unverified potency on top of the same patient-reconstitution dose-error class.
Regional U.S. poison-center data is consistent with the case-series finding: GLP-1-related calls roughly doubled from 2023 to 2024 across multiple state systems, with compounded and unregulated sources driving the majority of the increase.
Legal paths to tirzepatide in 2026
If the underlying goal is tirzepatide for chronic weight management or type 2 diabetes, three legal paths exist as of November 2026:
Path 1: LillyDirect Self Pay Pharmacy ($299-$449/month)
Eli Lilly’s direct-to-patient pharmacy, LillyDirect Self Pay, dispenses Zepbound at cash prices of $299 for 2.5 mg, $399 for 5 mg, and $449 for each higher dose on Lilly’s 45-day refill program ($499–$699 at the regular price) for the KwikPen, with single-dose vials starting at $299 (Lilly’s Zepbound savings page, November 2026; prices subject to change). The vial format requires a syringe draw, but either format is genuine brand Zepbound from the FDA-approved manufacturing chain, with all USP quality testing intact. A prescription is required; LillyDirect routes you through a partnered telehealth clinician if you do not have one.
Path 2: Commercial insurance with prior authorization
Many commercial insurance plans cover Zepbound for chronic weight management when prior authorization is obtained — usually a BMI threshold, a weight-related comorbidity, and sometimes a documented lifestyle-intervention attempt. Mounjaro is widely covered for type 2 diabetes. Coverage varies substantially by payer and plan; see our guide to finding a GLP-1 prescriber near you for the workflow and the per-payer prior-authorization references.
Path 3: Patient-specific 503A compounded tirzepatide for clinical necessity
Section 503A compounding remains lawful in the United States for patient-specific prescriptions driven by a documented clinical reason the FDA-approved product cannot be used — for example, a documented allergy to a Zepbound or Mounjaro inactive ingredient, or a documented dose strength not available in the approved product. This is a narrow medical-necessity carve-out, not a commercial business model. It is the reason a fraction of the previously-large compounded-tirzepatide industry has persisted; it is not a replacement for the broader pre-February-2025 compounded market.
For the deeper landscape — including the verification checks for any pharmacy that claims 503A authority — see buying tirzepatide online: how to verify pharmacy legitimacy and where to buy tirzepatide legally. For the legal prescription route step by step, see how to get tirzepatide online.
What FDA enforcement actually looks like for personal possession
Honest framing on the question many readers actually have: federal criminal prosecution of an individual buyer for a single vial of research-chemical tirzepatide for self-use is uncommon. The FDA and DOJ allocate enforcement resources toward sellers, distributors, importers, and large-volume buyers. That said, the more common practical outcomes for an individual buyer include:
- Customs seizure of inbound shipments. Tirzepatide has an FDA-approved domestic equivalent, so personal-importation policy does not protect inbound vials from foreign suppliers. Seized product is not refunded.
- Payment-processor reversals. Visa, Mastercard, Stripe, and PayPal routinely unwind merchant accounts identified as unapproved-drug sellers; pending orders may evaporate without refund.
- Adverse-event blind spot. A research-chemical tirzepatide adverse event has no FDA-traceable manufacturer to report to, no FAERS pathway, and no product liability path. The treating ER physician will not have a product label, lot number, or batch record to consult.
- Contamination outcomes. Bacterial endotoxin contamination at the injection site produces injection-site reactions; systemic endotoxemia can produce fever, hypotension, and sepsis. Identity-mismatch products (a different peptide sold as tirzepatide) produce idiosyncratic responses with no published clinical playbook.
- Resale and distribution. Where personal possession becomes resale — including informal “sharing” with friends or family for compensation — the buyer becomes a distributor of an unapproved new drug, and the federal-prosecution calculus changes materially.
Bottom line
- Tirzepatide sold as a “research peptide” for personal injection is the distribution and receipt of an unapproved new drug under the Federal Food, Drug, and Cosmetic Act. The “research use only” disclaimer is the seller’s legal shield, not a quality guarantee, and it does not legalize personal therapeutic use.
- The FDA enforcement-discretion window for compounded tirzepatide closed on February 18, 2025 (503A state-licensed pharmacies) and March 19, 2025 (503B outsourcing facilities). Broad commercial compounded tirzepatide is no longer permitted. Research-peptide tirzepatide was never on the legal side of the line.
- Research-chemical tirzepatide has no verified identity, purity, sterility, endotoxin, or dose accuracy. The dose-error class behind the 10-fold semaglutide overdoses in the published case series applies even more sharply to vials shipped from unregistered chemistry suppliers.
- The three legal paths to tirzepatide in 2026 are FDA-approved brand Zepbound or Mounjaro through a retail pharmacy or LillyDirect Self Pay Pharmacy ($299-$449/month for Zepbound; Mounjaro from $499), commercial-insurance coverage with prior authorization, or narrow patient-specific 503A compounded tirzepatide for documented clinical necessity. None of those paths is gray-market.
- Federal criminal prosecution of an individual buyer for self-use is uncommon, but Customs seizure of inbound shipments, payment-processor reversals, the adverse-event blind spot, and the contamination outcomes are all routine. The downside distribution is large; the regulatory shield is not real.
Our reviews
Providers that offer tirzepatide
Telehealth providers we’ve reviewed. Each opens our full, independent review.
Featured partners
Partners · our scores never change
- Editorial score: 7.7. Read our review of Ivim HealthCompounded GLP-1 with weekly provider check-ins and health coaches, under a required monthly membershipFrom$117/mo+ required membershipcompounded
- Editorial score: 7.7. Read our review of TrimRxBest overall valueFrom$279/mostarting dosecompounded
- Editorial score: 7.6. Read our review of Belle HealthFlat-rate compounded GLP-1 with weekly dietitian check-ins and long-plan discountsFrom$249/mocompounded
- Editorial score: 7.6. Read our review of MaximusMen seeking compounded tirzepatide alongside testosterone optimizationFrom$100/mo12-month plan ratecompounded
- Editorial score: 7.6. Read our review of SkinnyRxCompounded semaglutide or tirzepatide with the consult and free overnight shipping in one priceFrom$299/moafter intro offercompounded
We may earn a commission from featured partners. Learn more
See the full ranking →Frequently Asked Questions
Further reading
- Top compounded-GLP-1 bioequivalence and quality studies
- Top compounded vs brand GLP-1 questions on Reddit, answered
- Top tirzepatide weight-loss studies (curated PubMed reading list)
- Counterfeit & fake semaglutide: how to spot it — the FDA/WHO-documented counterfeit-Ozempic problem and how to verify a legitimate product
Weight Loss Rankings does not prescribe, dispense, or endorse any specific medication, compounding pharmacy, or gray-market product. Specific seller domains are deliberately not named to avoid driving readers toward unlawful channels; the category-level diagnostic patterns are the same regardless of seller branding.
References
- 1.Coskun T, Sloop KW, Loghin C, Alsina-Fernandez J, Urva S, Bokvist KB, Cui X, Briere DA, Cabrera O, Roell WC, Kuchibhotla U, Moyers JS, Benson CT, Gimeno RE, D'Alessio DA, Haupt A. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Tirzepatide is a 39-amino-acid dual GIP/GLP-1 receptor agonist peptide; molecular weight 4810.52 Da as reported in the paper; structurally derived from a native GIP backbone with C20 fatty-diacid acylation for albumin binding and once-weekly dosing. Mol Metab. 2018. PMID: 30473097.
- 2.Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A; SURMOUNT-1 Investigators. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). Subcutaneous tirzepatide 5 mg, 10 mg, and 15 mg once weekly produced mean body-weight reductions of -15.0%, -19.5%, and -20.9% respectively versus -3.1% placebo at 72 weeks in 2,539 adults with obesity. The trial enrolled and dosed the brand FDA-approved injectable formulation; no research-chemical or grey-market product was tested. N Engl J Med. 2022. PMID: 35658024.
- 3.Lambson JE, Flegal SC, Johnson AR. Administration errors of compounded semaglutide reported to a poison control center — Case series. Three cases of adverse events after incorrect administration of compounded semaglutide, including two self-administered 10-fold dosing errors; syringes not intended for semaglutide added to confusion over dosing units (mL, units, mg). The same dosing-error class is relevant to any non-brand lyophilized GLP-1 product, including research-chemical tirzepatide. J Am Pharm Assoc (2003). 2023. PMID: 37392810.
- 4.U.S. Food and Drug Administration. Declaratory Order: Resolution of Shortages of Tirzepatide. December 19, 2024. FDA reconfirmed that the tirzepatide shortage was resolved; enforcement-discretion deadlines for compounded tirzepatide set at February 18, 2025 (503A state-licensed pharmacies) and March 19, 2025 (503B outsourcing facilities). U.S. Food and Drug Administration. 2024. https://www.fda.gov/media/184606/download
- 5.U.S. Food and Drug Administration. Resolution of Tirzepatide Injection Product Shortage and Enforcement Discretion. December 19, 2024. FDA Declaratory Order on enforcement-discretion timeline for state-licensed pharmacies (503A) and outsourcing facilities (503B) compounding tirzepatide injection products after shortage resolution. U.S. Food and Drug Administration. 2024. https://www.fda.gov/media/185577/download
- 6.U.S. Food and Drug Administration. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. Standing FDA postmarket safety advisory cataloguing the agency's concerns with compounded, counterfeit, and grey-market GLP-1 receptor agonist products marketed for weight loss outside the FDA-approved supply chain. U.S. Food and Drug Administration. 2025. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
- 7.U.S. Food and Drug Administration. FDA Clarifies Policies for Compounders as National GLP-1 Supply Begins to Stabilize. Agency statement explaining the post-shortage compounding policy framework for tirzepatide and semaglutide, including the section 503A and 503B enforcement-discretion timelines. U.S. Food and Drug Administration. 2025. https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize
- 8.U.S. Food and Drug Administration. FDA Alerts Health Care Providers, Compounders and Patients of Dosing Errors Associated with Compounded Injectable Semaglutide Products. October 2024 alert documenting reports of multi-fold dosing errors with compounded injectable semaglutide. Same risk class applies to any non-brand lyophilized GLP-1 product, including 'research peptide' tirzepatide. U.S. Food and Drug Administration. 2024. https://www.fda.gov/drugs/human-drug-compounding/fda-alerts-health-care-providers-compounders-and-patients-dosing-errors-associated-compounded
- 9.U.S. Food and Drug Administration. FDA Warns Consumers Not to Use Counterfeit Ozempic (semaglutide) Found in U.S. Drug Supply Chain. December 2023 consumer-safety alert documenting counterfeit Ozempic 1 mg lots in the legitimate U.S. supply chain with counterfeit needles of unverified sterility. Illustrative of the contamination and counterfeiting risk landscape for any non-brand GLP-1 product, including research-chemical tirzepatide. U.S. Food and Drug Administration. 2023. https://www.fda.gov/drugs/drug-alerts-and-statements/fda-warns-consumers-not-use-counterfeit-ozempic-semaglutide-found-us-drug-supply-chain
- 10.U.S. Food and Drug Administration. Drugs@FDA: FDA-Approved Drugs — Zepbound (tirzepatide) injection. NDA 217806; Eli Lilly and Company; FDA-approved November 8, 2023 for chronic weight management. Companion record: NDA 215866 Mounjaro (tirzepatide) injection, FDA-approved May 13, 2022 for type 2 diabetes. No generic tirzepatide has FDA approval or tentative approval as of November 2026. U.S. Food and Drug Administration. 2026. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217806
Related research
Can You Still Get Compounded Tirzepatide in 2026? Current FDA Status
FDA removed tirzepatide from the shortage list October 2024 and the litigation paused enforcement through March 2025 — now compounded tirz is restricted to 503A patient-specific scripts. We map who can still legally dispense, who can't, and the four exceptions.
12 min read
Is Ozempic Available Over the Counter? Honest 2026 Evidence Review
No. Ozempic is a prescription-only drug regulated under 21 CFR Part 503. It cannot be purchased OTC at any US retailer. This article walks the four legitimate Rx pathways, the OTC supplement scam landscape, and FDA / FTC enforcement against fake 'natural Ozempic' products.
11 min read
Is There a GLP-1 Supplement? The Honest Evidence Review on 'Natural Ozempic' OTC Products
No OTC supplement contains a GLP-1 receptor agonist. Products sold as 'GLP-1 supplements' or 'natural Ozempic' are berberine, capsaicin, fiber, chromium, or ACV — small effects via unrelated mechanisms, roughly 10x weaker than Wegovy or Zepbound. Honest evidence review.
15 min read
Can You Still Get Compounded Semaglutide in 2026? Current FDA Status
Only narrowly. FDA declared the semaglutide shortage resolved on February 21, 2025, so compounding survives mainly as 503A patient-specific prescriptions where a prescriber documents a need approved products cannot meet. Cost and convenience do not qualify.
11 min read
FDA Warning Letters to Compounded GLP-1 Telehealth Providers: The Live Investigation
A tracked set of FDA warning letters to compounded GLP-1 telehealth providers and compounding pharmacies, with the violation patterns, most-cited statutes, and issuing offices, and which business models should make you cautious. The dataset is rebuilt from the FDA's public index.
10 min read
How to Get Tirzepatide Online (2026): Brand vs Compounded, Legit Pathways & Cost
How to get tirzepatide online safely in 2026: the GIP/GLP-1 molecule in Zepbound and Mounjaro, brand vs compounded, who can prescribe, LillyDirect self-pay vials, telehealth, cost by pathway, and the red flags to avoid.
11 min read
Where to get tirzepatide (Mounjaro / Zepbound) safely: vetted online providers
Vetted telehealth providers that prescribe online. We compare pricing, form, and states served.
No insurance needed · vetted by our editors
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. How we make money
Gala
Compounded semaglutide or tirzepatide at one all-doses price on a yearly plan, with free shipping
Read full review →From $179/mo (prepaid plan rate)
Get started →Found
Medication-included compounded GLP-1 from $169/mo on a 12-month prepaid plan, plus brand insurance help
Read full review →From $239/mo (12-month plan rate)
Get started →Oak
Compounded semaglutide and tirzepatide at a low starting price, with a full price list before you sign up
Read full review →From $250/mo (starting dose)
Get started →